AstraZeneca plc (LON:AZN) was upgraded by research analysts at Bryan, Garnier & Co to a “buy” rating in a report issued on Monday. The brokerage currently has a GBX 5,380 ($69.48) price objective on the biopharmaceutical company’s stock, up from their prior price objective of GBX 4,700 ($60.70). Bryan, Garnier & Co’s price objective points to a potential upside of 9.24% from the stock’s previous close.
A number of other equities research analysts have also issued reports on AZN. Deutsche Bank AG increased their target price on shares of AstraZeneca plc from GBX 5,350 ($69.09) to GBX 5,700 ($73.61) and gave the stock a “buy” rating in a report on Monday, May 15th. HSBC Holdings plc reiterated a “reduce” rating and set a GBX 4,200 ($54.24) target price on shares of AstraZeneca plc in a report on Monday, May 15th. Shore Capital upgraded shares of AstraZeneca plc to a “hold” rating and set a GBX 4,800 ($61.99) target price on the stock in a report on Tuesday, May 16th. Berenberg Bank increased their target price on shares of AstraZeneca plc from GBX 5,670 ($73.23) to GBX 5,850 ($75.55) and gave the stock a “buy” rating in a report on Wednesday, May 17th. Finally, Jefferies Group LLC set a GBX 4,700 ($60.70) target price on shares of AstraZeneca plc and gave the stock a “neutral” rating in a report on Saturday, May 20th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of GBX 4,963.82 ($64.11).
AstraZeneca plc (LON AZN) opened at 4887.50 on Monday. The firm has a 50-day moving average of GBX 4,566.85 and a 200 day moving average of GBX 4,882.53. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The stock’s market capitalization is GBX 61.88 billion.
ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Rating Increased to Buy at Bryan, Garnier & Co” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2017/09/13/astrazeneca-plc-azn-rating-increased-to-buy-at-bryan-garnier-co.html.
In other news, insider Nazneen Rahman bought 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.